Baseline demographics and disease characteristicsa | Episodic migraine N = 1338 | Chronic migraine N = 836 | ||
---|---|---|---|---|
Placebo (n = 894) | Galcanezumab 120 mg (n = 444) | Placebo (n = 558) | Galcanezumab 120 mg (n = 278) | |
Age (years), mean (SD) | 41.9 (11.4) | 40.9 (11.5) | 41.6 (12.1) | 39.7 (11.9) |
Gender (female), n (%) | 755 (84.5) | 378 (85.1) | 483 (86.6) | 237 (85.3) |
Race (white), n (%) | 681 (76.2) | 335 (75.5) | 432 (77.4) | 223 (80.2) |
Ethnicity (not Hispanic or Latino), n (%) | 677 (79.4) | 342 (80.1) | 401 (76.7) | 195 (74.7) |
Region, North America, n (%) | 657 (73.5) | 325 (73.2) | 321 (57.5) | 161 (57.9) |
Duration of migraine disease (years), mean (SD) | 20.5 (12.5) | 20.5 (12.3) | 21.9 (12.9) | 20.4 (12.7) |
Migraine headache days/month, mean (SD) | 9.1 (3.0) | 9.1 (3.0) | 19.6 (4.6) | 19.4 (4.3) |
MIDAS total score, mean (SD) | 33.1 (29.3) | 31.9 (28.0) | 68.7 (57.4) | 62.5 (49.5) |
MSQ total score, mean (SD) | 58.8 (16.4) | 58.2 (16.1) | 44.4 (17.9) | 45.2 (18.2) |
Total monthly pain severity-weighted duration in hours, mean (SD) | 123.9 (92.2) | 122.4 (90.5) | 321.2 (231.3) | 324.5 (212.0) |